Forskolin/rolipram liposomal - Innomedica
Alternative Names: Liposomal arteriosclerosis therapy - Innomedica; Rolipram/forskolin liposomal; TLFR-1Latest Information Update: 28 Apr 2022
Price :
$50 *
At a glance
- Originator InnoMedica
- Developer InnoMedica; University of Hawaii
- Class Antihyperlipidaemics
- Mechanism of Action Adenylate cyclase stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Atherosclerosis in Switzerland (Liposomal)
- 28 Apr 2020 Preclinical development is still ongoing for Atherosclerosis in Switzerland (Innomedica pipeline, April 2020)
- 22 May 2017 Suspended - Preclinical for Atherosclerosis in Switzerland (Liposomal) (InnoMedica communication, May 2017)